Skip to content
HomeLatest newsWhat you need to know about Johnson & Johnson’s 2020 third-quarter earnings
Lede-What You Need to Know About Johnson & Johnson's 2020 Third-Quarter Earnings.jpg

What you need to know about Johnson & Johnson’s 2020 third-quarter earnings

Check out this infographic breakdown of the company’s third-quarter 2020 performance, with key highlights from its consumer, pharmaceutical and medical devices businesses.

Inset - Quarterly Earnings Ribbon
2020 Q3 Earnings Infographic Johnson & Johnson

This morning, Johnson & Johnson shared its third-quarter performance.

Since its founding in 1886, the company has grown to become one of the world’s largest and most broadly based healthcare companies, with approximately 132,000 employees across the globe working every day to help change the trajectory of health for humanity.

“Johnson & Johnson’s solid third-quarter performance reflects the strength of our business model, the quality and breadth of our portfolio and our relentless drive toward innovation,” says Joseph Wolk, Executive Vice President, Chief Financial Officer, Johnson & Johnson. “We continue to be driven by our purpose to advance health for humanity as we work to accelerate the development of a safe, effective and affordable investigational COVID-19 vaccine candidate on a not-for-profit basis for pandemic use. The results in these extraordinary times were made possible by our colleagues around the world and their unwavering resilience and focus to deliver value to all of our stakeholders by providing healthcare solutions that benefit people in need globally.”

For more details about the company’s 2020 third-quarter results, and to read a message from Chairman and Chief Executive Officer Alex Gorsky, here’s an infographic that highlights key stats.


Want to see more company earnings information? Find Johnson & Johnson’s past quarterly and full-year results here.

More from Johnson & Johnson

This scientist couldn’t save his father from lung cancer—but the targeted treatments Robert Zhao, Ph.D., has since developed have helped countless others

Learn more about Zhao, his partnership with Johnson & Johnson and antibody-drug conjugates—a new type of cancer therapy that targets and kills cancer cells without harming healthy cells.

After their husbands were diagnosed with multiple myeloma, these 3 care partners became health equity activists

Kimberly Alexander, Michelle Ware-Ivy and Marsha Calloway-Campbell learned firsthand that Black individuals develop multiple myeloma at higher rates. That’s why they joined Johnson & Johnson’s That’s My Word® health equity campaign, which builds awareness about the disparities surrounding this rare blood cancer.

How Johnson & Johnson is working to get medications to people around the world who need them most

In the just-released 2024 Access to Medicine Index, the company ranks among the top 5 improving access to medicines.